Aandeel BDTX BLACK DIAMOND THERAPEUTICS, INC.
Toevoegen aan een lijst
Om deze functie te gebruiken moet u een klant of lid zijn.
InloggenRegistreren

Andere talen Black Diamond Therapeutics, Inc.

Aandelen

BDTX

US09203E1055

Beurs gesloten - Nasdaq
Andere beurzen
 22:00:00 14-06-2024 		Variatie 5 dagen Verschil t.o.v. 1 jan (%)
5,97 USD -3,24% Intraday-grafiek van Black Diamond Therapeutics, Inc. +15,03% +112,46%
01/06 Black Diamond Therapeutics, Inc. Presenteert veelbelovende klinische gegevens van Bdtx-1535 bij patiënten met terugkerend glioblastoom op de jaarlijkse bijeenkomst van de American Society of Clinical Oncology (Asco) in 2024 CI
16/05 BLACK DIAMOND THERAPEUTICS, INC. : HC Wainwright handhaaft koopadvies ZM

Andere talen

Zoeken op
Resultaten bekijken
Krijg toegang tot al het nieuws over alle bedrijven: mis nooit meer een winstgevende beleggingskans!
Gratis inschrijven
Black Diamond Therapeutics Presents Promising BDTX-1535 Clinical Data in Patients with Recurrent Glioblastoma at 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
Black Diamond Therapeutics, Inc. Presents Promising Bdtx-1535 Clinical Data in Patients with Recurrent Glioblastoma At 2024 American Society of Clinical Oncology Annual Meeting
Black Diamond Therapeutics Presents Promising BDTX-1535 Clinical Data in Patients with Recurrent Glioblastoma at 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
Black Diamond Therapeutics to Participate in Jefferies Global Healthcare Conference
Black Diamond Therapeutics to Participate in Jefferies Global Healthcare Conference
Black Diamond Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update
Black Diamond: Q1 Earnings Snapshot
Black Diamond Therapeutics : Reports First Quarter 2024 Financial Results and Provides Corporate Update - Form 8-K
Black Diamond Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024
Black Diamond Therapeutics Announces Presentations at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
Black Diamond Therapeutics, Inc. Announces Board and Committee Changes
Black Diamond Therapeutics Announces Changes to Board of Directors
Black Diamond Therapeutics Says BDTX-1535 Potentially Inhibits Non-Classical Mutations in Non-Small Cell Lung Cancer Patients
Black Diamond Therapeutics Presents Novel Real-World Evidence of the Evolving EGFR Mutation Landscape in NSCLC and the Opportunity for BDTX-1535 in an Oral Presentation at the 2024 American Association of Cancer Research Annual Meeting
Black Diamond Therapeutics Presents Novel Real-World Evidence of the Evolving EGFR Mutation Landscape in NSCLC and the Opportunity for BDTX-1535 in an Oral Presentation at the 2024 American Association of Cancer Research Annual Meeting
Black Diamond Therapeutics to Participate in Upcoming Investor Conferences
Black Diamond: Q4 Earnings Snapshot
Black Diamond Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
Black Diamond Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
Black Diamond Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
Geen resultaten voor deze zoekopdracht
Al het nieuws Aanbevelingen van analisten Belangrijkste gebeurtenissen Insiders Transcripties Persberichten Officiële publicaties Andere talen Ideeën voor de handel MarketScreener-artikels MarketScreener-analyses

Filters

Zoeken op

Datum van publicatie

Sinds de

Tot

  1. Beurs
  2. Aandelen
  3. Koers BDTX
  4. Nieuws Black Diamond Therapeutics, Inc.
  5. Andere talen